Drug Interactions between levoketoconazole and taletrectinib
This report displays the potential drug interactions for the following 2 drugs:
- levoketoconazole
- taletrectinib
Interactions between your drugs
levoketoconazole taletrectinib
Applies to: levoketoconazole and taletrectinib
Consumer information for this interaction is not currently available.
CONTRAINDICATED: Coadministration with levoketoconazole may significantly increase the plasma concentrations of drugs that are sensitive CYP450 3A4 substrates or combined CYP450 3A4 and P-glycoprotein (P-gp) substrates. Levoketoconazole is a strong inhibitor of the CYP450 3A4 isoenzyme and an inhibitor of the P-gp efflux transporter. Increased exposure to CYP450 3A4 or combined CYP450 3A4 and P-gp substrates that can prolong the QT interval may increase the risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, levoketoconazole itself can cause QT interval prolongation and may have additive effects with these agents. According to cardiac electrophysiology data provided by the prescribing information, the largest mean increase in QTc was 24 msec following administration of levoketoconazole 150 mg to 600 mg twice daily in patients with endogenous Cushing's syndrome, and the increase was dose-related. During two premarketing levoketoconazole clinical studies, 4 (2.4%) patients experienced QTcF greater than 500 msec, and 23 (14.7%) patients presented a change in QTcF greater than 60 msec from baseline. The clinical studies did not include patients with baseline QTcF interval greater than 470 msec.
MANAGEMENT: Concomitant use of levoketoconazole with sensitive CYP450 3A4 substrates or combined CYP450 3A4 and P-gp substrates that can prolong the QT interval is considered contraindicated.
Drug and food/lifestyle interactions
taletrectinib food/lifestyle
Applies to: taletrectinib
Consumer information for this interaction is not currently available.
GENERALLY AVOID: Coadministration with grapefruit juice may increase the plasma concentrations of taletrectinib. The proposed mechanism for the interaction is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. Inhibition of hepatic CYP450 3A4 may also contribute. The interaction has not been studied with grapefruit juice but has been reported for other CYP450 3A4 inhibitors. In a clinical study, taletrectinib peak plasma concentration (Cmax) increased by 1.8-fold and systemic exposure (AUC) increased by 3.3-fold following concomitant administration of itraconazole, a potent CYP450 3A inhibitor. According to the product labeling, administration of taletrectinib with a moderate CYP450 3A inhibitor is predicted to increase taletrectinib Cmax and AUC by up to 1.5- and 2.6-fold, respectively. Increased exposure to taletrectinib may increase the risk and/or severity of adverse effects such as hepatotoxicity with liver enzyme elevations, lung toxicities, QT prolongation, hyperuricemia, myalgia with creatine phosphokinase elevation, and skeletal fractures.
ADJUST DOSING INTERVAL: Coadministration with high-fat food (1000 calories, 50% fat) increased taletrectinib Cmax and AUC by 1.5-fold, and the predicted increase in the QTc interval is 20.5 msec.
MANAGEMENT: The manufacturer recommends avoiding food or drink containing grapefruit during treatment with taletrectinib. In addition, taletrectinib should be administered on an empty stomach at about the same time each day, at least 2 hours before or 2 hours after food intake.
levoketoconazole food/lifestyle
Applies to: levoketoconazole
You should avoid the use of alcohol while being treated with levoketoconazole. Levoketoconazole may cause liver damage and using it with alcohol or products containing alcohol may increase that risk. In addition, consumption of alcoholic beverages or products containing alcohol during treatment with levoketoconazole may trigger a disulfiram-like reaction in some patients, with unpleasant symptoms such as flushing, palpitations, and nausea. Levoketoconazole may be taken with or without food. You should avoid consumption of grapefruit, grapefruit juice, or any supplements that contain grapefruit extract during treatment with levoketoconazole unless directed otherwise by your doctor. Grapefruit juice may increase the blood levels of levoketoconazole. This may increase the risk and/or severity of side effects and liver problems. You should seek immediate medical attention if you develop signs and symptoms of liver damage during treatment with levoketoconazole, such as joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, dark colored urine, light colored stools, and yellowing of the skin or eyes. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.